BPC-157
Also known as Body Protection Compound 157
Synthetic pentadecapeptide derived from a gastric protective protein, studied for cytoprotective and tissue-repair effects.
This compound was removed from FDA Category 2 in 2026, but final action on the 503A compounding list is still pending. Allora does not currently dispense it — join the waitlist and we will notify you if it becomes available through our licensed pharmacy partners.
Mechanism of action
How BPC-157 works
Modulates angiogenesis, growth-factor signaling, and inflammatory cascades to support repair across soft tissue and gastrointestinal mucosa.
Areas of study
What BPC-157 is studied for
- check
Soft tissue, tendon, and ligament repair
- check
Gastrointestinal mucosal protection
- check
Adjunctive recovery after orthopedic injury
Considerations
Important things your physician will discuss
This is general clinical context — not medical advice. Your evaluation determines whether BPC-157 is appropriate for you.
- info
Removed from FDA Category 2 in 2026; final action on the 503A compounding list is pending — currently offered as educational information and waitlist only
- info
Not approved as a finished pharmaceutical in the United States
- info
Sport governing bodies may restrict use — disclose if you compete
- info
Not appropriate during active malignancy or pregnancy
Related peptides
More from the Regenerative category
TB-500 / Thymosin Beta-4
Synthetic fragment of Thymosin Beta-4 studied for cell migration, angiogenesis, and tissue remodeling.
View peptide arrow_outwardCopper-binding peptideGHK-Cu
Naturally occurring copper-binding tripeptide offered as a topical preparation, studied for collagen synthesis and skin regeneration.
View peptide arrow_outwardThis compound is pending FDA compounding review.
We don't dispense it today. Join the waitlist and we'll notify you if it becomes available through our licensed pharmacy partners.